ANA PINHEIRO MACHADO CANTON
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/42 - Laboratório de Hormônios e Genética Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/42 - Laboratório de Hormônios e Genética Molecular, Hospital das Clínicas, Faculdade de Medicina
12 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 12
- The Congenital and Acquired Mechanisms Implicated in the Etiology of Central Precocious Puberty(2023) BRITO, Vinicius N.; CANTON, Ana P. M.; SERAPHIM, Carlos Eduardo; ABREU, Ana Paula; MACEDO, Delanie B.; MENDONCA, Berenice B.; KAISER, Ursula B.; ARGENTE, Jesus; LATRONICO, Ana ClaudiaThe etiology of central precocious puberty (CPP) is multiple and heterogeneous, including congenital and acquired causes that can be associated with structural or functional brain alterations. All causes of CPP culminate in the premature pulsatile secretion of hypothalamic GnRH and, consequently, in the premature reactivation of hypothalamic-pituitary-gonadal axis. The activation of excitatory factors or suppression of inhibitory factors during childhood represent the 2 major mechanisms of CPP, revealing a delicate balance of these opposing neuronal pathways. Hypothalamic hamartoma (HH) is the most well-known congenital cause of CPP with central nervous system abnormalities. Several mechanisms by which hamartoma causes CPP have been proposed, including an anatomical connection to the anterior hypothalamus, autonomous neuroendocrine activity in GnRH neurons, trophic factors secreted by HH, and mechanical pressure applied to the hypothalamus. The importance of genetic and/or epigenetic factors in the underlying mechanisms of CPP has grown significantly in the last decade, as demonstrated by the evidence of genetic abnormalities in hypothalamic structural lesions (eg, hamartomas, gliomas), syndromic disorders associated with CPP (Temple, Prader-Willi, Silver-Russell, and Rett syndromes), and isolated CPP from monogenic defects (MKRN3 and DLK1 loss-of-function mutations). Genetic and epigenetic discoveries involving the etiology of CPP have had influence on the diagnosis and familial counseling providing bases for potential prevention of premature sexual development and new treatment targets in the future. Global preventive actions inducing healthy lifestyle habits and less exposure to endocrine-disrupting chemicals during the lifespan are desirable because they are potentially associated with CPP.
- Methylome profiling of healthy and central precocious puberty girls(2018) BESSA, Danielle S.; MASCHIETTO, Mariana; AYLWIN, Carlos Francisco; CANTON, Ana P. M.; BRITO, Vinicius N.; MACEDO, Delanie B.; CUNHA-SILVA, Marina; PALHARES, Heloisa M. C.; RESENDE, Elisabete A. M. R. de; BORGES, Maria de Fatima; MENDONCA, Berenice B.; NETCHINE, Irene; KREPISCHI, Ana C. V.; LOMNICZI, Alejandro; OJEDA, Sergio R.; LATRONICO, Ana ClaudiaBackgroundRecent studies demonstrated that changes in DNA methylation (DNAm) and inactivation of two imprinted genes (MKRN3 and DLK1) alter the onset of female puberty. We aimed to investigate the association of DNAm profiling with the timing of human puberty analyzing the genome-wide DNAm patterns of peripheral blood leukocytes from ten female patients with central precocious puberty (CPP) and 33 healthy girls (15 pre- and 18 post-pubertal). For this purpose, we performed comparisons between the groups: pre- versus post-pubertal, CPP versus pre-pubertal, and CPP versus post-pubertal.ResultsAnalyzing the methylome changes associated with normal puberty, we identified 120 differentially methylated regions (DMRs) when comparing pre- and post-pubertal healthy girls. Most of these DMRs were hypermethylated in the pubertal group (99%) and located on the X chromosome (74%). Only one genomic region, containing the promoter of ZFP57, was hypomethylated in the pubertal group. ZFP57 is a transcriptional repressor required for both methylation and imprinting of multiple genomic loci. ZFP57 expression in the hypothalamus of female rhesus monkeys increased during peripubertal development, suggesting enhanced repression of downstream ZFP57 target genes. Fourteen other zinc finger (ZNF) genes were related to the hypermethylated DMRs at normal puberty. Analyzing the methylome changes associated with CPP, we demonstrated that the patients with CPP exhibited more hypermethylated CpG sites compared to both pre-pubertal (81%) and pubertal (89%) controls. Forty-eight ZNF genes were identified as having hypermethylated CpG sites in CPP.ConclusionMethylome profiling of girls at normal and precocious puberty revealed a widespread pattern of DNA hypermethylation, indicating that the pubertal process in humans is associated with specific changes in epigenetically driven regulatory control. Moreover, changes in methylation of several ZNF genes appear to be a distinct epigenetic modification underlying the initiation of human puberty.
bookPart Idiopathic short stature: diagnostic and therapeutic approach(2014) CANTON, Ana P. M.; JORGE, Alexander A. L.- Diagnosis and management of Silver-Russell syndrome: first international consensus statement(2017) WAKELING, Emma L.; BRIOUDE, Frederic; LOKULO-SODIPE, Oluwakemi; O'CONNELL, Susan M.; SALEM, Jennifer; BLIEK, Jet; CANTON, Ana P. M.; CHRZANOWSKA, Krystyna H.; DAVIES, Justin H.; DIAS, Renuka P.; DUBERN, Beatrice; ELBRACHT, Miriam; GIABICANI, Eloise; GRIMBERG, Adda; GRONSKOV, Karen; HOKKEN-KOELEGA, Anita C. S.; JORGE, Alexander A.; KAGAMI, Masayo; LINGLART, Agnes; MAGHNIE, Mohamad; MOHNIKE, Klaus; MONK, David; MOORE, Gudrun E.; MURRAY, Philip G.; OGATA, Tsutomu; PETIT, Isabelle Oliver; RUSSO, Silvia; SAID, Edith; TOUMBA, Meropi; TUMER, Zeynep; BINDER, Gerhard; EGGERMANN, Thomas; HARBISON, Madeleine D.; TEMPLE, I. Karen; MACKAY, Deborah J. G.; NETCHINE, IreneThis Consensus Statement summarizes recommendations for clinical diagnosis, investigation and management of patients with Silver-Russell syndrome (SRS), an imprinting disorder that causes prenatal and postnatal growth retardation. Considerable overlap exists between the care of individuals born small for gestational age and those with SRS. However, many specific management issues exist and evidence from controlled trials remains limited. SRS is primarily a clinical diagnosis; however, molecular testing enables confirmation of the clinical diagnosis and defines the subtype. A 'normal' result from a molecular test does not exclude the diagnosis of SRS. The management of children with SRS requires an experienced, multidisciplinary approach. Specific issues include growth failure, severe feeding difficulties, gastrointestinal problems, hypoglycaemia, body asymmetry, scoliosis, motor and speech delay and psychosocial challenges. An early emphasis on adequate nutritional status is important, with awareness that rapid postnatal weight gain might lead to subsequent increased risk of metabolic disorders. The benefits of treating patients with SRS with growth hormone include improved body composition, motor development and appetite, reduced risk of hypoglycaemia and increased height. Clinicians should be aware of possible premature adrenarche, fairly early and rapid central puberty and insulin resistance. Treatment with gonadotropin-releasing hormone analogues can delay progression of central puberty and preserve adult height potential. Long-term follow up is essential to determine the natural history and optimal management in adulthood.
- Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg)(2021) RAMOS, Carolina O.; CANTON, Ana P. M.; SERAPHIM, Carlos Eduardo; FARIA, Aline Guimaraes; TINANO, Flavia Rezende; MENDONCA, Berenice B.; LATRONICO, Ana C.; BRITO, Vinicius N.Objectives: Longer-acting gonadotropin-releasing hormone analogs (GnRHa) have been widely used for central precocious puberty (CPP) treatment. However, the followup of patients after this treatment are still scarce. Our aim was to describe anthropometric, metabolic, and reproductive follow-up of CPP patients after treatment with leuprorelin acetate 3-month depot (11.25 mg). Methods: Twenty-two female patients with idiopathic CPP were treated with leuprorelin acetate 3-month depot (11.25 mg). Their medical records were retrospectively evaluated regarding clinical, hormonal, and imaging aspects before, during, and after GnRHa treatment until adult height (AH). Results: At the diagnosis of CPP, the mean chronological age (CA) was 8.2 +/- 1.13 year, and mean bone age (BA) was 10.4 +/- 1.4 year. Mean height SDS at the start and the end of GnRHa treatment was 1.6 +/- 0.8 and 1.3 +/- 0.9, respectively. The mean duration of GnRHa treatment was 2.8 +/- 0.8 year. Mean predicted adult heights (PAH) at the start and the end of GnRH treatment was 153.2 +/- 8.6 and 164.4 +/- 7.3 cm, respectively (p<0.05). The mean AH was 163.2 +/- 6.2 cm (mean SDS: 0.1 +/- 1). All patients were within their target height (TH) range. There was a decrease in the percentage of overweight and obesity from the diagnosis until AH (39-19% p>0.05). At the AH, the insulin resistance and high LDL levels were identified in 3/17 patients (17.6%) and 2/21 patients (9.5%), respectively. The mean CA of menarche was 12.2 +/- 0.5 years. At the AH, PCOS was diagnosed in one patient (4.8%). Conclusions: Long-term anthropometric, metabolic, and reproductive follow-up of patients with CPP treated with longer-acting GnRHa revealed effectivity, safety, and favorable outcomes.
- Familial central precocious puberty due to DLK1 deficiency: novel genetic findings and relevance of serum DLK1 levels(2023) MONTENEGRO, Luciana; SERAPHIM, Carlos; TINANO, Flavia; PIOVESAN, Maiara; CANTON, Ana P. M.; MCELREAVEY, Ken; BRABANT, Severine; BORIS, Natalia P.; MAGNUSON, Melissa; CARROLL, Rona S.; KAISER, Ursula B.; ARGENTE, Jesus; BARRIOS, Vicente; BRITO, Vinicius N.; BRAUNER, Raja; LATRONICO, Ana ClaudiaBackground: Several rare loss-of-function mutations of delta-like noncanonical notch ligand 1 (DLK1) have been described in non-syndromic children with familial central precocious puberty (CPP). Objective: We investigated genetic abnormalities of DLK1 gene in a French cohort of children with idiopathic CPP. Additionally, we explored the pattern of DLK1 serum levels in patients with CPP and in healthy children at puberty, as well as in wild-type female mice. Patients and Methods: Genomic DNA was obtained from 121 French index cases with CPP. Automated sequencing of the coding region of the DLK1 gene was performed in all cases. Serum DLK1 levels were measured by enzyme linked immunosorbent assay (ELISA) in 209 individuals, including 191 with normal pubertal development and in female mice during postnatal pubertal maturation. Results: We identified 2 rare pathogenic DLK1 allelic variants: A stop gain variant (c.372C>A; p.Cys124X) and a start loss variant (c.2T>G; p.Met1?, or p.0) in 2 French girls with CPP. Mean serum DLK1 levels were similar between healthy children and idiopathic CPP children. In healthy individuals, DLK1 levels correlated with pubertal stage: In girls, DLK1 decreased between Tanner stages III and V, whereas in boys, DLK1 decreased between Tanner stages II and V (P =.008 and.016, respectively). Serum levels of Dlk1 also decreased in wild-type female mice. Conclusions: Novel loss-of-function mutations in DLK1 gene were identified in 2 French girls with CPP. Additionally, we demonstrated a pattern of dynamic changes in circulating DLK1 serum levels in humans and mice during pubertal stages, reinforcing the role of this factor in pubertal timing.
conferenceObject Long Term Effects of Childhood Growth Hormone Treatment on Height and Body Mass Index in Adolescents and Adults with Silver-Russell Syndrome(2018) LOKULO-SODIPE, Oluwakemi; CANTON, Ana P. M.; GIABICANI, Eloise; FERRAND, Nawfel; CHILD, Jenny; WAKELING, Emma L.; BINDER, Gerhard; NETCHINE, Irene; MACKAY, Deborah J. G.; INSKIP, Hazel M.; BYRNE, Christopher D.; DAVIES, Justin H.; TEMPLE, I. Karen- Genome-wide screening of copy number variants in children born small for gestational age reveals several candidate genes involved in growth pathways(2014) CANTON, Ana P. M.; COSTA, Silvia S.; RODRIGUES, Tatiane C.; BERTOLA, Debora R.; MALAQUIAS, Alexsandra C.; CORREA, Fernanda A.; ARNHOLD, Ivo J. P.; ROSENBERG, Carla; JORGE, Alexander A. L.Background: The etiology of prenatal-onset short stature with postnatal persistence is heterogeneous. Submicroscopic chromosomal imbalances, known as copy number variants (CNVs), may play a role in growth disorders. Objective: To analyze the CNVs present in a group of patients born small for gestational age (SGA) without a known cause. Patients and methods: A total of 51 patients with prenatal and postnatal growth retardation associated with dysmorphic features and/or developmental delay, but without criteria for the diagnosis of known syndromes, were selected. Array-based comparative genomic hybridization was performed using DNA obtained from all patients. The pathogenicity of CNVs was assessed by considering the following criteria: inheritance; gene content; overlap with genomic coordinates for a known genomic imbalance syndrome; and overlap with CNVs previously identified in other patients with prenatal- onset short stature. Results: In 17 of the 51 patients, 18 CNVs were identified. None of these imbalances has been reported in healthy individuals. Nine CNVs, found in eight patients (16%), were categorized as pathogenic or probably pathogenic. Deletions found in three patients overlapped with known microdeletion syndromes (4q, 10q26, and 22q11.2). These imbalances are de novo, gene rich and affect several candidate genes or genomic regions that may be involved in the mechanisms of growth regulation. Conclusion: Pathogenic CNVs in the selected patients born SGA were common (at least 16%), showing that rare CNVs are probably among the genetic causes of short stature in SGA patients and revealing genomic regions possibly implicated in this condition.
- Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study(2023) CANTON, Ana P. M.; TINANO, Flavia R.; GUASTI, Leonardo; MONTENEGRO, Luciana R.; RYAN, Fiona; SHEARS, Deborah; MELO, Maria Edna de; GOMES, Larissa G.; PIANA, Mariana P.; BRAUNER, Raja; ESPINO-AGUILAR, Rafael; ESCRIBANO-MUNOZ, Arancha; PAGANONI, Alyssa; READ, Jordan E.; KORBONITS, Marta; SERAPHIM, Carlos E.; COSTA, Silvia S.; KREPISCHI, Ana Cristina; JORGE, Alexander A. L.; DAVID, Alessia; KAISINGER, Lena R.; ONG, Ken K.; PERRY, John R. B.; ABREU, Ana Paula; KAISER, Ursula B.; ARGENTE, Jesus; MENDONCA, Berenice B.; BRITO, Vinicius N.; HOWARD, Sasha R.; LATRONICO, Ana ClaudiaBackground Identification of genetic causes of central precocious puberty have revealed epigenetic mechanisms as regulators of human pubertal timing. MECP2, an X-linked gene, encodes a chromatin-associated protein with a role in gene transcription. MECP2 loss-of-function mutations usually cause Rett syndrome, a severe neurodevelopmental disorder. Early pubertal development has been shown in several patients with Rett syndrome. The aim of this study was to explore whether MECP2 variants are associated with an idiopathic central precocious puberty phenotype. Methods In this translational cohort study, participants were recruited from seven tertiary centres from five countries (Brazil, Spain, France, the USA, and the UK). Patients with idiopathic central precocious puberty were investigated for rare potentially damaging variants in the MECP2 gene, to assess whether MECP2 might contribute to the cause of central precocious puberty. Inclusion criteria were the development of progressive pubertal signs (Tanner stage 2) before the age of 8 years in girls and 9 years in boys and basal or GnRH-stimulated LH pubertal concentrations. Exclusion criteria were the diagnosis of peripheral precocious puberty and the presence of any recognised cause of central precocious puberty (CNS lesions, known monogenic causes, genetic syndromes, or early exposure to sex steroids). All patients included were followed up at the outpatient clinics of participating academic centres. We used high-throughput sequencing in 133 patients and Sanger sequencing of MECP2 in an additional 271 patients. Hypothalamic expression of Mecp2 and colocalisation with GnRH neurons were determined in mice to show expression of Mecp2 in key nuclei related to pubertal timing regulation. Findings Between Jun 15, 2020, and Jun 15, 2022, 404 patients with idiopathic central precocious puberty (383 [95%] girls and 21 [5%] boys; 261 [65%] sporadic cases and 143 [35%] familial cases from 134 unrelated families) were enrolled and assessed. We identified three rare heterozygous likely damaging coding variants in MECP2 in five girls: a de novo missense variant (Arg97Cys) in two monozygotic twin sisters with central precocious puberty and microcephaly; a de novo missense variant (Ser176Arg) in one girl with sporadic central precocious puberty, obesity, and autism; and an insertion (Ala6_Ala8dup) in two unrelated girls with sporadic central precocious puberty. Additionally, we identified one rare heterozygous 3 & PRIME;UTR MECP2 insertion (36_37insT) in two unrelated girls with sporadic central precocious puberty. None of them manifested Rett syndrome. Mecp2 protein colocalised with GnRH expression in hypothalamic nuclei responsible for GnRH regulation in mice. Interpretation We identified rare MECP2 variants in girls with central precocious puberty, with or without mild neurodevelopmental abnormalities. MECP2 might have a role in the hypothalamic control of human pubertal timing, adding to the evidence of involvement of epigenetic and genetic mechanisms in this crucial biological process.
- Height and body mass index in molecularly confirmed Silver-Russell syndrome and the long-term effects of growth hormone treatment(2022) LOKULO-SODIPE, Oluwakemi; GIABICANI, Eloise; CANTON, Ana P. M.; FERRAND, Nawfel; CHILD, Jenny; WAKELING, Emma L.; BINDER, Gerhard; NETCHINE, Irene; MACKAY, Deborah J. G.; INSKIP, Hazel M.; BYRNE, Christopher D.; TEMPLE, I. Karen; DAVIES, Justin H.Objective Silver-Russell syndrome (SRS) causes short stature. Growth hormone (GH) treatment aims to increase adult height. However, data are limited on the long-term outcomes of GH in patients with molecularly confirmed SRS. This study evaluated height, body mass index (BMI) and GH treatment in molecularly confirmed SRS. Design An observational study with retrospective data collection. Patients Individuals with molecularly confirmed SRS aged >= 13 years. Measurements Data were collected on height, height gain (change in height standard deviation score [SDS] from childhood to final or near-final height), BMI and gain in BMI (from childhood to adulthood) and previous GH treatment. Results Seventy-one individuals (40 female) were included. The median age was 22.0 years (range 13.2-69.7). The molecular diagnoses: H19/IGF2:IG-DMR LOM in 80.3% (57/71); upd(7)mat in 16.9% (12/71) and IGF2 mutation in 2.8% (2/71). GH treatment occurred in 77.5% (55/71). Total height gain was greater in GH-treated individuals (median 1.53 SDS vs. 0.53 SDS, p = .007), who were shorter at treatment initiation (-3.46 SDS vs. -2.91 SDS, p = .04) but reached comparable heights to GH-untreated individuals (-2.22 SDS vs. -2.74 SDS, p = .7). In GH-treated individuals, BMI SDS was lower at the most recent assessment (median -1.10 vs. 1.66, p = .002) with lower BMI gain (2.01 vs. 3.58, p = .006) despite similar early BMI SDS to GH-untreated individuals (median -2.65 vs. -2.78, p = .3). Conclusions These results support the use of GH in SRS for increasing height SDS. GH treatment was associated with lower adult BMI which may reflect improved metabolic health even following discontinuation of therapy.